ClinicalTrials.gg
CompletedNCT07053345Updated Aug 3, 2026

A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

A Phase 4 interventional study of Esketamine 56 mg and Esketamine 84 mg in Depressive Disorder, Treatment-Resistant, sponsored by Janssen Korea, Ltd., Korea. Completed at 6 sites in South Korea. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.

Enrollment
14th of 18
47 · median 210
Started
2025
with 1 other
Phase 4
4 of 18
1 open now
Registered
17th of 18
by date
Lead sponsor
1 of 18
Janssen Korea, Ltd., Korea

Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 14th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 4, and was the 17th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).

03

Conditions studied

  • Depressive Disorder, Treatment-Resistant
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a confirmed diagnosis of major depressive disorder (MDD) according to the , Fifth Edition at the time of enrollment, without psychotic features, based on clinical assessment, and confirmed by mini international neuropsychiatric interview (MINI)
  • Must have a Hamilton depression rating scale (HAM-D; 17-item) total score greater than or equal to (>=) 22 at screening and Day 1
  • Participants must have had non-response (less than or equal to [\<=] 25 percent [%] improvement of symptoms) to >= 2 oral antidepressant treatments in the current moderate to severe episode of depression after having been given at an adequate dosage for an adequate duration of at least 6 weeks
  • At baseline (Day 1), the investigator will evaluate any changes in the participant's signs/symptoms of depression since the screening assessment and confirm that the inclusion criteria for the current antidepressant (AD) treatment are still met (that is, nonresponse and minimal clinical improvement)
  • A female participant of must have a negative serum pregnancy test at screening and urine prior to the first dose of study intervention on Day 1

Exclusion criteria

Exclusion Criteria:

  • Participants with hyperthyroidism that has not been sufficiently treated
  • History of within 5 years of enrollment before screening
  • Known allergies, , or intolerance to esketamine/ketamine or its
  • Received an intervention or used an invasive investigational medical device within 60 days before the planned first dose of study intervention or first data collection time point
  • Currently enrolled in an investigational study that involves treatments for MDD or may otherwise be expected to impact mood
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Esketamine Nasal Spray

    Participants will self-administer one esketamine (flexibly dosed; 56 or 84 milligrams \[mg\]) nasal spray into each nostril (that is, a total of 2 sprays using 1 intranasal device) twice a week for 4 weeks. For 84 mg, sprays to each nostril will be delivered in rapid succession at 3 different time points (3 devices total). 56 mg will have 2 devices.

    Drug: Esketamine 56 mg · Drug: Esketamine 84 mg

Interventions

  • Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.

    Also known as: JNJ-54135419

  • Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.

    Also known as: JNJ-54135419

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 28 in Hamilton Depression Rating Scale (HAM-D) Total Score

    The HAM-D contains 17 items pertaining to symptoms of depression experienced over the past week. The questions cover core symptoms of depression as well as appetite and sleep (3 items). Items are scored on a likert scale of 0-4 or 0-2 depending on the item with a possible range of 0-52, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline up to Day 28

Secondary outcomes

  1. Change From Baseline Over Time for HAM-D Total Score

    The HAM-D contains 17 items pertaining to symptoms of depression experienced over the past week. The questions cover core symptoms of depression as well as appetite and sleep (3 items). Items are scored on a likert scale of 0-4 or 0-2 depending on the item with a possible range of 0-52, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline up to Week 4

  2. Change From Baseline Over Time for Patient Health Questionnaire 9-item (PHQ-9) Total Score

    The PHQ-9 is a validated 9-item, patient-reported outcomes (PRO) measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) major depressive disorder (MDD) criteria and it has been used both as a screening tool and a measure of response to treatment for depression. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline up to Week 4

  3. Percentage of Participants With Response Based on HAM-D Total Score Over Time

    Percentage of participants with response based on HAM-D total score over time will be reported. The HAM-D contains 17 items pertaining to symptoms of depression experienced over the past week. The questions cover core symptoms of depression as well as appetite and sleep (3 items). Items are scored on a likert scale of 0-4 or 0-2 depending on the item with a possible range of 0-52, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Up to Week 4

  4. Percentage of Participants With Response Based on PHQ-9 Total Score Over Time

    Percentage of participants with response based on PHQ-9 total score over time will be reported. The PHQ-9 is a validated 9-item, PRO measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the DSM-5 MDD criteria and it has been used both as a screening tool and a measure of response to treatment for depression. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.

    Time frame: Up to Week 4

  5. Percentage of Participants With Remission Based on HAM-D Total Score Over Time

    Percentage of participants with remission based on HAM-D total score over time will be reported. The HAM-D contains 17 items pertaining to symptoms of depression experienced over the past week. The questions cover core symptoms of depression as well as appetite and sleep (3 items). Items are scored on a likert scale of 0-4 or 0-2 depending on the item with a possible range of 0-52, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Up to Week 4

  6. Percentage of Participants With Remission Based on PHQ-9 Total Score Over Time

    Percentage of participants with remission based on PHQ-9 total score over time will be reported. The PHQ-9 is a validated 9-item, PRO measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the DSM-5 MDD criteria and it has been used both as a screening tool and a measure of response to treatment for depression. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.

    Time frame: Up to Week 4

  7. Percentage of Participants With Clinically Meaningful Improvement Based on HAM-D Total Score Over Time

    Percentage of participants with clinically meaningful improvement based on HAM-D total score over time will be reported. The HAM-D contains 17 items pertaining to symptoms of depression experienced over the past week. The questions cover core symptoms of depression as well as appetite and sleep (3 items). Items are scored on a likert scale of 0-4 or 0-2 depending on the item with a possible range of 0-52, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Up to Week 4

  8. Percentage of Participants With Clinically Meaningful Improvement Based on PHQ-9 Total Score Over Time

    Percentage of participants with clinically meaningful improvement based on total score PHQ-9 total score over time will be reported. The PHQ-9 is a validated 9-item, PRO measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the DSM-5 MDD criteria and it has been used both as a screening tool and a measure of response to treatment for depression. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.

    Time frame: Up to Week 4

  9. Change From Baseline Over Time for Clinical Global Impression-Severity (CGI-S) Score

    The CGI-S is a clinician-rated scales that measure illness severity. The CGI has proved to be a robust measure of efficacy in many clinical drug trials and is easy and quick to administer. The CGI-S is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (among the most severely ill participants).

    Time frame: Baseline up to Week 4

07

Study locations

6 sites
  • Cha Ilsan Medical Center
    Goyang Si Gyeonggi Do, 10414, South Korea
  • Wonkwang University Hospital
    Iksan, 570 711, South Korea
  • Kangbuk Samsung Hospital
    Seoul, 03181, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Kyung Hee University Hospital
    Seoul, 130 050, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jul 2026, 13 months.

Of 18 phase 4 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 59. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 8, 2025
StartActual
Jun 9, 2025
Primary completionActual
Jul 13, 2026
CompletionActual
Jul 13, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07053345
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Jun 9, 2025
Primary completion
Jul 13, 2026
Completion
Jul 13, 2026
Last update
Aug 3, 2026

Study contacts

Janssen Korea, Ltd., Korea Clinical Trial
study director · Janssen Korea, Ltd., Korea

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion